Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

We review the current literature and describe 10 tips for non-pharmacological interventions with the potential to modify fracture risk in CKD patients: appropriate intake of calcium and vitamin D, adequate nutrition and protein intake, avoidance of smoking and alcohol, medication review, reinforcement of exercise, reducing risk of home hazards, prevention of orthostatic hypotension, taking care of neuropathy and determining fall risk, as well as implementing fracture liaison services, are all actions of relevance to the patient with CKD-associated osteoporosis.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Publisher article type: review-article

Source: Publisher publication metadata.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Ten tips to reduce fracture risk by non-pharmacologic interventions in CKD-associated osteoporosis

Review / evidence synthesis · Clinical Kidney Journal · 2026

Original publication title

Ten tips to reduce fracture risk by non-pharmacologic interventions in CKD-associated osteoporosis

Ditte Hansen; Hanne Skou-Jørgensen; Mehmet Kanbay; Maria Fusaro; Louise Salomo; Susanne Fleig; Stig Molsted; Jesper Ryg; Mathias Haarhaus; Pieter Evenepoel

© The Author(s) 2026. Published by Oxford University Press on behalf of the ERA.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

ABSTRACT

Chronic kidney disease (CKD)-associated osteoporosis is present in approximately 25% of all patients with CKD. The occurrence increases as kidney function declines, with prevalences up to 75% in elderly dialysis patients. It is often undiagnosed due to the perception that limited treatment options are available for this condition. This inappropriate assumption leads to diagnostic and therapeutic nihilism. The effect-size of pharmacological interventions on bone mineral density in patients with CKD is comparable to or higher than in other forms of osteoporosis.

Non-pharmacological interventions can improve bone strength and fracture risk in addition to pharmacological interventions. Importantly, they are often applicable to patients with CKD without restrictions, with some specific considerations in end-stage kidney disease. Due to the increased prevalence of modifiable risk factors for fragility fractures in CKD, non-pharmacological interventions should be provided to all patients with CKD-associated osteoporosis. We review the current literature and describe 10 tips for non-pharmacological interventions with the potential to modify fracture risk in CKD patients: appropriate intake of calcium and vitamin D, adequate nutrition and protein intake, avoidance of smoking and alcohol, medication review, reinforcement of exercise, reducing risk of home hazards, prevention of orthostatic hypotension, taking care of neuropathy and determining fall risk, as well as implementing fracture liaison services, are all actions of relevance to the patient with CKD-associated osteoporosis.

As in the general population, non-pharmacological interventions should be the first option to consider when osteoporosis is diagnosed. With this paper, we suggest how this should be tailored to the patient with CKD.

Authors’ abstract

ABSTRACT

Chronic kidney disease (CKD)-associated osteoporosis is present in approximately 25% of all patients with CKD. The occurrence increases as kidney function declines, with prevalences up to 75% in elderly dialysis patients. It is often undiagnosed due to the perception that limited treatment options are available for this condition. This inappropriate assumption leads to diagnostic and therapeutic nihilism. The effect-size of pharmacological interventions on bone mineral density in patients with CKD is comparable to or higher than in other forms of osteoporosis.

Non-pharmacological interventions can improve bone strength and fracture risk in addition to pharmacological interventions. Importantly, they are often applicable to patients with CKD without restrictions, with some specific considerations in end-stage kidney disease. Due to the increased prevalence of modifiable risk factors for fragility fractures in CKD, non-pharmacological interventions should be provided to all patients with CKD-associated osteoporosis. We review the current literature and describe 10 tips for non-pharmacological interventions with the potential to modify fracture risk in CKD patients: appropriate intake of calcium and vitamin D, adequate nutrition and protein intake, avoidance of smoking and alcohol, medication review, reinforcement of exercise, reducing risk of home hazards, prevention of orthostatic hypotension, taking care of neuropathy and determining fall risk, as well as implementing fracture liaison services, are all actions of relevance to the patient with CKD-associated osteoporosis.

As in the general population, non-pharmacological interventions should be the first option to consider when osteoporosis is diagnosed. With this paper, we suggest how this should be tailored to the patient with CKD.

Publication and source details

Original title: Ten tips to reduce fracture risk by non-pharmacologic interventions in CKD-associated osteoporosis

Ditte Hansen; Hanne Skou-Jørgensen; Mehmet Kanbay; Maria Fusaro; Louise Salomo; Susanne Fleig; Stig Molsted; Jesper Ryg; Mathias Haarhaus; Pieter Evenepoel

Clinical Kidney Journal · 2026

Correspondence to: Ditte Hansen; E-mail: ditte.hansen.04@regionh.dk© The Author(s) 2026. Published by Oxford University Press on behalf of the ERA.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:45:21.560218+00:00

DOI: 10.1093/ckj/sfag303 · PMC13627839